条条大路通罗马？

候月

阻断乙肝病毒表面抗原
多么振奋人心！

肝胆相照009

值得关注！！！科技的发展远远超出常人的想象

j369

又是一个希望，应大力支持，比较、鉴别，选择适合自己的。但不能以刻薄的文字去讽刺。大家说，对吗？

宫崎骏

我的小三阳什么时候转阴？愁死了。我是母婴传播的。

色迷心窍

楼主，发自己的贴，让2B们骂去吧

肝胆相照009

"it won't take long to have it on the market ",VERY GOOD!!!
不知道三月份报道的结果怎么样？

j369

richard2010

这个新药是可以减少hbvdna，还是可以减低hbsag呢？

--阻断乙肝病毒表面抗原.还在临床试验阶段，如若成功，所有其它抗病毒药都可能停产，药厂可要亏钱了，病患可要一劳永逸了，庸医可得它处去害人行骗了，良医可得攀登其它珠穆朗玛峰了。

那6个人是表面抗原转阴了呢？还是DNA转阴呢？？？？？？？

谁能纤细说一下这个药呢？？

肝胆相照009

REP 9AC的二期临床试验在北京所汇报的结果，很振奋人心，看到希望了

shiweibuyi

初步证据治疗慢性乙型肝炎（CHB）是DNA为基础的双亲性聚合物的快速治疗乙肝表面抗原血清转换。

马蒙铝马赫塔卜，米歇尔巴齐内，安德鲁瓦扬

背景：REP9AC是DNA为基础的两亲聚合物，其抗病毒活性，是针对病毒糖蛋白与病毒性项目和重要/或释放。 28天9AC图谱坚持治疗与鸭乙型肝炎病毒感染鸭临床前的评价表明，在55个鸭的血鸭乙型肝炎病毒感染并没有检测鸭乙型肝炎病毒的DNA的证据％，DHBsAg和反地区保健委员会迅速出现迅速清除抗体后停止16周图谱9AC治疗。该图谱9AC能力治疗慢性乙型肝炎患者人类目前正在评估的概念试验证明。

方法：慢性乙型肝炎患者遭受REP9AC治疗缓慢持续输注。安全和病毒学应答（乙肝病毒脱氧核糖核酸，乙肝表面抗原，抗- HBs）每周进行评估，或者在审判现场或通过在一个单独的验证性测试使用的位置（乙肝表面抗原，e抗原，抗- HBs，抗- HBe血清样本的冷冻） ArchitectTM测试平台。结果：临时数据显示，所有患者治疗至今已清除乙肝表面抗原和发展保护性免疫。 HBsAg和抗- HBs的保护水平的发展，早在清发生后7天，在较高剂量开始治疗。在抽象提交时，一名病人已经出现乙型肝炎表面抗原 - e抗原 - 抗- HBs +，抗- HBe +）连续治疗8周后关闭收到持续病毒学应答（HBV DNA的 - 明显的迹象只有23周同REP9AC治疗。

结论：这些结果表明，两亲聚合物在迅速减少乙肝表面抗原在慢性乙型肝炎患者，让患者seroconvert的水平。在抗- HBs，而在这些患者抗- HBe抗体，支持向量回归的最好预测CHB患者，迅速出现表明，两亲聚合物可以成为重要的慢性乙型肝炎的治疗提供新的工具。

Preliminary Evidence of Rapid HBsAg Seroconversion in Patients with Chronic Hepatitis B (CHB) Treated with a DNA-based Amphipathic Polymer.

Mamun Al-Mahtab, Michel Bazinet, Andrew Vaillant

Background: REP9AC is a DNA-based amphipathic polymer whose antiviral activity is linked to targeting viral glycoproteins important for viral entry and/ or release. The preclinical evaluation of 28 days of REP 9AC therapy in ducks persistently infected with DHBV demonstrated rapid clearance of DHBV DNA, DHBsAg and rapid appearance of anti-DHBs antibodies in 55% of ducks whose blood had no detectable evidence of DHBV infection 16 weeks after cessation of REP 9AC therapy. The ability of REP 9AC to treat human patients with CHB is currently being evaluated in a proof of concept trial.

Methods: Patients with CHB were subjected to REP9AC therapy administered by slow continuous infusion. Safety and virologic response (HBV DNA, HBsAg, anti-HBs) were assessed weekly, either at the trial site or by confirmatory testing (HBsAg, HBeAg, anti-HBs, anti-HBe) of frozen serum samples at a separate location using the ArchitectTM testing platform. Results: Interim data has shown that all patients treated to date have cleared HBsAg and developed protective immunity. Clearance of HBsAg and development of protective levels of anti-HBs occurred as early as 7 days following initiation of treatment at higher doses. At the time of abstract submission, one patient has already exhibited clear signs of a sustained virologic response (HBV DNA -, HBsAg -, HBeAg -, anti-HBs +, anti-HBe +) for 8 continuous weeks off treatment after receiving only 23 weeks of treatment with REP9AC.

Conclusions: These results demonstrate that amphipathic polymers are effective in rapidly reducing HBsAg levels in CHB patients which allows patients to seroconvert. The rapid appearance of anti-HBs and anti-HBe antibodies in these patients, the best predictors of SVR in patients with CHB, suggest that amphipathic polymers could become an important new tool in the treatment of CHB.

[ 本帖最后由 shiweibuyi 于 2010-4-2 07:12 编辑 ]